跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Diamyd Medical AB

首页临床试验发起方与机构Diamyd Medical AB

Diamyd Medical AB

ACTIVE

Stockholm, 瑞典www.diamyd.comPublic25 名员工成立于: 1994-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

20

15 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

1994

概览

试验阶段分布

阶段

试验数

占比

1 期

15

75.0%

2 期

4

20.0%

3 期

1

5.0%

试验状态分布

进行中（未招募）

15

75.0%

已完成

1

5.0%

招募中

3

15.0%

终止

1

5.0%

相关临床试验

该机构主办的试验（20）

Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

进行中（未招募）

Jul 20245 名受试者

A Study to evaluate the safety and feasibility of Diamyd® in individuals at risk for Type 1 diabetes

进行中（未招募）

Jun 202416 名受试者

A clinical study to investigate if the investigational drug Diamyd works in adolescents and adults with a specific type 1 diabetes that has recently been diagnosed. The safety of Diamyd will also be investigated. Some subjects may receive a placebo drug.

进行中（未招募）

May 2024330 名受试者

A clinical trial to investigate the safety and feasibility of the intralymphatic administration of the investigational drug Diamyd in children at risk to develop type-1 diabetes

进行中（未招募）

Oct 202216 名受试者

A clinical study to investigate if the investigational drug Diamyd works in adolescents and adults with a specific type 1 diabetes that has recently been diagnosed. The safety of Diamyd will also be investigated. Some subjects may receive a placebo drug.

进行中（未招募）

Jul 2022330 名受试者

A clinical study to investigate if the investigational drug Diamyd works in adolescents and adults with a specific type 1 diabetes that has recently been diagnosed. The safety of Diamyd will also be investigated. Some subjects may receive a placebo drug.

Jul 2022330 名受试者

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

May 2022321 名受试者

A clinical study to investigate if the investigational drug Diamyd works in adolescents and adults with a specific type 1 diabetes that has recently been diagnosed. The safety of Diamyd will also be investigated. Some subjects may receive a placebo drug.

进行中（未招募）

Oct 2021330 名受试者

第 1 页，共 3 页

药物批准

暂无批准数据

资讯

Type 1 Diabetes Pipeline Shows Robust Growth with 85+ Companies Developing 100+ Therapeutic Candidates

- DelveInsight's 2025 pipeline report reveals 85+ companies actively developing over 100 therapeutic candidates for Type 1 diabetes treatment, indicating a robust and expanding research landscape. - Key emerging therapies include Vertex Pharmaceuticals' VX-880 stem cell-derived islet cell therapy, Eli Lilly's long-acting insulin Efsitora Alfa in Phase III trials, and Sanofi's frexalimab targeting immune pathways. - Recent clinical developments include Creative Medical Technology's CELZ-201 Phase I/IIa trial and NIDDK's 78-participant study evaluating abrocitinib and ritlecitinib treatments. - The pipeline spans diverse therapeutic approaches from traditional insulin therapies to innovative stem cell treatments and immune system modulators, addressing various aspects of Type 1 diabetes management.

Diamyd Medical's DIAGNODE-3 Trial Exceeds Recruitment Target for Early Readout

- Diamyd Medical's DIAGNODE-3 trial, a Phase 3 precision medicine study, has recruited 180 patients, surpassing the target for its planned early readout in March 2026. - The early readout is intended to support a potential accelerated Biologics License Application (BLA) to the FDA for Diamyd® in Type 1 Diabetes. - DIAGNODE-3 evaluates Diamyd®, an antigen-specific immunotherapy, in individuals with newly diagnosed Stage 3 Type 1 Diabetes, focusing on the HLA DR3-DQ2 haplotype. - The trial assesses the preservation of endogenous insulin production (C-peptide) and glycemic control (HbA1c) over 24 months in approximately 330 patients.

本页目录

概览
相关临床试验20
药物批准
资讯2

返回机构列表